The "Acute Lung Injury - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
Acute Lung Injury - Pipeline Insight, 2019 offers a comprehensive insight of the pipeline (under development) therapeutics scenario and growth prospects across Acute Lung Injury development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:
- Clinical
- Non-clinical
- Inactive: Discontinued and/or Dormant
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Scope of the Report
- The report provides a snapshot of the pipeline development for the Acute Lung Injury
- The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Acute Lung Injury
- The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Acute Lung Injury
- The report also covers the dormant and discontinued pipeline projects related to Acute Lung Injury
Companies Featured
- Altor BioScience Corp.
- Asklepion Pharmaceuticals LLC
- Commence Bio Inc.
- CompleGen Inc.
- GlaxoSmithKline PLC
- Histocell
- Lung Therapeutics Inc.
- Navigen Pharmaceuticals Inc.
- Quark Pharmaceuticals Inc.
- S-Evans Biosciences Inc.
- Silence Therapeutics PLC
Topics Covered
1. Report Introduction
2. Acute Lung Injury Overview
3. Pipeline Therapeutics
- An Overview of Pipeline Products for Acute Lung Injury
4. Comparative Analysis
5. Products in Clinical Stage
5.1 Drug Name : Company Name
- Product Description
- Research and Development
- Product Development Activities
6. Products in Pre-Clinical and Discovery Stage
6.1 Drug Name : Company Name
- Product Description
- Research and Development
- Product Development Activities
7. Therapeutic Assessment
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
8. Inactive Products
8.1 Drug Name : Company Name
- Product Description
- Research and Development
-
Product Development Activities
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/mzw2w9/acute_lung_injury?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20190313005386/en/
Contacts:
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Respiratory
Drugs